On June 27, 2025, Bone Biologics Corp announced a public offering, pricing 793,750 shares and pre-funded warrants to purchase additional shares at $4.00 each, aiming to raise approximately $4.3 million for clinical trials and working capital. The offering closed on June 30, 2025, with potential gross proceeds of around $10 million if all warrants are exercised.